The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Haemalogix
Sydney, Australia
A
1-10 Employees
-
Key takeaway
HaemaLogiX is actively developing bispecific antibodies that target unique antigens on malignant bone marrow cells, aiming to enhance treatment outcomes for patients with blood cancers, particularly multiple myeloma. Their experienced team and scientific advisory board specialize in antibody research and immunotherapy development.
Reference
Product
Technology | HaemaLogiX
Following the discovery of two unique antigens on malignant Bone Marrow Cells, HaemaLogiX is developing Monoclonal Antibodies, CAR T cell Therapies and Bispecific Antibodies that specifically target those malignant cells.
Myrio Tx
Melbourne, Australia
A
11-50 Employees
2009
Key takeaway
Myrio Therapeutics is focused on developing antibody-based therapies that can target intracellular proteins, including those associated with cancer and viral infections. Their innovative Retained DisplayTM (ReD) technology enhances the discovery of therapeutic antibodies.
Reference
Core business
Homepage - Myrio Tx
Anthrocell Pty Ltd
Sydney, Australia
A
11-50 Employees
2010
Key takeaway
Anthrocell Pty Ltd is an Australian biotechnology company focused on the commercialization of innovative biopharmaceutical production technologies. Their platform, the Anthrocell Expression System (ACX™), enhances the clinical effectiveness and production efficiency of human therapeutic drugs, which may include advancements relevant to bispecific antibodies.
Reference
Core business
AnthroCell – Fully Human Biopharmaceuticals
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Bioprocess
Sydney, Australia
A
- Employees
-
Key takeaway
The company is currently evolving its focus towards the generation of recombinant polypeptides, which may include bispecific antibodies, in response to the growing interest in novel proteins spurred by advancements in genomics. Their in-house capabilities encompass all steps from gene product conceptualization to evaluation, often in collaboration with external partners.
Reference
Core business
Company - Bioprocess
Biosensis Pty Ltd
Adelaide, Australia
A
11-50 Employees
2006
Key takeaway
Biosensis is dedicated to supporting researchers in their quest for innovative solutions in disease prevention, diagnosis, and treatment. They specialize in providing high-quality antibodies and related products, particularly for Neuroscience and Cancer research.
Reference
Product
Quality antibodies for Cancer research!
Biotome Pty Ltd
Perth, Australia
A
1-10 Employees
2017
Key takeaway
Biotome is developing next-generation antibody diagnostics that enhance the understanding of the immune system, which is relevant to the field of bispecific antibodies. Their innovative approach has the potential to impact the diagnosis and treatment of various diseases.
Reference
Core business
Next Generation Antibody Diagnostics | Biotome
At Biotome, we are developing next generation antibody diagnostics that unlock the high-resolution of the immune system. Our efficient, scalable discovery pipeline is applicable to a huge number of diseases.
NeuClone
Sydney, Australia
A
- Employees
2007
Key takeaway
NeuClone is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of high-quality biosimilars, employing a Biosimilarity by Design™ approach that ensures quality and cost-effectiveness. This expertise may be relevant for those interested in the advancements of bispecific antibodies within the biosimilar landscape.
Reference
Core business
NeuClone | Increasing Patient Access
Gamma Biomedical
Gold Coast City, Australia
A
11-50 Employees
2014
Key takeaway
Gamma Biomedical is a multinational healthcare company focused on providing niche pharmaceutical products to Australian healthcare professionals. They emphasize collaboration with industry leaders to deliver high-quality biomedical products and services.
Reference
Core business
About | Gamma Biomedical
Immulab-Immunohaematology
Melbourne, Australia
A
11-50 Employees
1939
Key takeaway
Immulab is focused on developing and manufacturing In-Vitro Diagnostics reagents for blood grouping and antibody screening, which are crucial for ensuring compatible blood transfusions. Their commitment to quality and innovation in immunohaematology enhances diagnostic confidence and patient safety.
Reference
Core business
About the Immulab Team | Blood bank products | IVD's
TGR BioSciences
Adelaide, Australia
A
11-50 Employees
2001
Key takeaway
TGR BioSciences specializes in immunoassay technology, offering innovative solutions for cell-based research applications. Their patented CaptSure™ technology enhances assay performance and efficiency, making it a valuable resource for measuring signaling proteins.
Reference
Core business
TGR BioSciences
Technologies which have been searched by others and may be interesting for you:
When exploring the bispecific antibody industry in Australia, several key considerations are essential. The regulatory environment is critical, as the Therapeutic Goods Administration (TGA) oversees the approval of biopharmaceuticals. Companies must navigate complex regulations that govern clinical trials, safety assessments, and market entry. Additionally, understanding the competitive landscape is vital; Australia hosts a mix of established pharmaceutical companies and innovative biotech startups, each vying for market share. Researching partnerships and collaborations can provide insights into emerging technologies and potential market leaders. The bispecific antibody market presents various opportunities, particularly in oncology and immunotherapy, as these treatments gain traction. However, challenges such as high development costs and the need for specialized manufacturing capabilities must be considered. Environmental concerns also play a role, as the industry increasingly focuses on sustainable practices and reducing its carbon footprint. Finally, it's essential to recognize the global market relevance, as Australia is becoming a hub for biopharmaceutical research and development, attracting international investment and talent. Keeping these factors in mind can offer a comprehensive view of the bispecific antibody landscape in Australia and aid in identifying promising companies in this evolving sector.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | Australia |
| Amount of fitting manufacturers | 60 |
| Amount of suitable service providers | 41 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1939 |
| Youngest suiting company | 2017 |
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Biotechnology, Other, Pharmaceuticals, Medical, Consulting
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
